Invectys : Dennis J. Purcell (Aisling Capital) join Adv...
Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC Paris, France, May…
Read more
Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC Paris, France, May…
Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells These results open new perspectives in oncology for targeting cancer through HLA-G,…
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
The main product of Invectys is a DNA vaccine targeting Telomerase…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…